New triple therapy may finally knock out tough stomach bug

NCT ID NCT05874544

Completed Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a three-drug combination containing rifabutin can wipe out Helicobacter pylori infections that didn't respond to earlier treatments. 360 adults who had failed prior therapy were randomly assigned to one of three regimens. The goal was to see which approach had the highest eradication rate six weeks after treatment ended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifabutin (antibiotic) combined with vonoprazan (acid reducer) and amoxicillin (antibiotic)
What this could lead to: If successful, this could provide a more effective rescue treatment for people with hard-to-treat H. pylori infections, reducing the risk of ulcers and stomach cancer.
What could go wrong: This is a completed Phase 4 trial, but results may not apply to all populations. Rifabutin can cause side effects like low white blood cell counts and may not work if resistance develops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTION

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200127, China
Shanghai Songjiang District Central Hospital

Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital of Zhejiang University school of Medicine

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.